Short Interest in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Declines By 22.8%

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) saw a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 4,093,770 shares, a decline of 22.8% from the December 15th total of 5,301,959 shares. Currently, 8.5% of the company’s shares are sold short. Based on an average daily volume of 379,867 shares, the short-interest ratio is presently 10.8 days. Based on an average daily volume of 379,867 shares, the short-interest ratio is presently 10.8 days. Currently, 8.5% of the company’s shares are sold short.

Insider Activity

In other DiaMedica Therapeutics news, major shareholder Jan Stahlberg acquired 240,352 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The stock was acquired at an average price of $7.21 per share, for a total transaction of $1,732,937.92. Following the acquisition, the insider directly owned 8,375,092 shares in the company, valued at $60,384,413.32. This represents a 2.95% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders purchased a total of 1,061,277 shares of company stock valued at $7,632,627 over the last three months. Corporate insiders own 7.30% of the company’s stock.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. bought a new position in shares of DiaMedica Therapeutics during the 3rd quarter worth about $27,000. Police & Firemen s Retirement System of New Jersey acquired a new position in DiaMedica Therapeutics during the 2nd quarter worth approximately $29,000. Bank of America Corp DE boosted its holdings in DiaMedica Therapeutics by 3,710.3% in the second quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after acquiring an additional 8,274 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in DiaMedica Therapeutics in the second quarter valued at approximately $49,000. Finally, Invesco Ltd. acquired a new stake in DiaMedica Therapeutics in the second quarter valued at approximately $54,000. 10.12% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DMAC has been the topic of a number of research reports. Cantor Fitzgerald initiated coverage on shares of DiaMedica Therapeutics in a report on Friday, November 14th. They set an “overweight” rating on the stock. Lake Street Capital restated a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Wall Street Zen lowered DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Wednesday, October 8th. Finally, Cowen started coverage on DiaMedica Therapeutics in a research report on Thursday, October 30th. They set a “buy” rating for the company. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.33.

DiaMedica Therapeutics Stock Performance

Shares of DMAC stock traded down $0.97 during mid-day trading on Friday, hitting $7.57. The company’s stock had a trading volume of 614,875 shares, compared to its average volume of 190,724. The company has a market cap of $394.22 million, a PE ratio of -10.66 and a beta of 1.15. The company’s fifty day simple moving average is $8.11 and its 200-day simple moving average is $6.63. DiaMedica Therapeutics has a 52 week low of $3.19 and a 52 week high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its earnings results on Wednesday, November 12th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). On average, equities analysts anticipate that DiaMedica Therapeutics will post -0.59 earnings per share for the current year.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.